Comera Life Sciences Appoints Michael Campbell as Executive Vice President and Chief Financial Officer
June 16 2022 - 8:00AM
Business Wire
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life
sciences company developing a new generation of bio-innovative
biologic medicines to improve patient access, safety, and
convenience, today announced the appointment of Michael Campbell as
Executive Vice President and Chief Financial Officer. He had served
as interim Chief Financial Officer since April 13, 2022 and will
continue to oversee Comera’s finance operations, including
accounting and reporting, corporate tax, treasury and investor
relations.
“We are excited that Michael will continue as our Chief
Financial Officer after serving in an interim capacity since April.
He brings extensive expertise and leadership in business finance
across the medical device and medical diagnostics industries and
will be a strong addition to our leadership team as we embark on
our new chapter as a public company,” said Jeff Hackman, Chief
Executive Officer and Chairman of Comera. “This is an exciting time
for Comera with a number of partnerships underway, and we are
well-positioned to help maximize the true potential of
life-changing biologics by transforming them from intravenous to
subcutaneous forms that patients can administer themselves.”
Campbell has over 30 years of financial leadership experience
across global public companies, spanning corporate finance,
accounting and reporting, investor relations, corporate tax,
international business operations and merger and acquisitions.
Prior to joining Comera as a consultant through Monomoy Advisors
LLC, Campbell held several senior finance leadership roles at Ortho
Clinical Diagnostics, including serving in the Office of the CFO
and as Vice President, Corporate Controller and Head of Global Tax.
Campbell held various senior leadership positions within Boston
Scientific Corporation, including Vice President of Investor
Relations and regional CFO as Vice President of Finance, Asia
Pacific and Emerging Markets based in Singapore. While at Boston
Scientific, Campbell was actively involved in over 20 acquisitions
and more than 100 strategic alliances and oversaw business segments
covering more than 40 countries. Early in Campbell’s career, he was
a Financial and Information Systems Assurance Manager at Ernst
& Young. Campbell received a B.S. degree in Accountancy from
Bentley University and is a Certified Public Account.
“I am excited to leverage my experience to help drive the
company’s business and financial growth as we execute on our
strategic vision,” said Campbell. “I am thrilled to join a
mission-driven company that is building a compassionate new era in
medicine and I look forward to working with the Comera leadership
team as we work to improve patient lives and deliver value for our
shareholders.”
About Comera Life Sciences Leading a compassionate new
era in medicine, Comera Life Sciences is applying a deep knowledge
of formulation science and technology to transform essential
biologic medicines from intravenous (IV) to subcutaneous (SQ)
forms. The goal of this approach is to provide patients with the
freedom of self-injectable care, reduce institutional dependency
and to put patients at the center of their treatment regimen.
To learn more about the Comera Life Sciences mission, as well as
the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
Forward-Looking Statements This press release contains
includes “forward-looking statements” within the meaning of the
federal securities laws. These forward-looking statements generally
are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
document, including, but not limited to: risks that the recently
completed business combination disrupts the Company’s current plans
and ability to retain its employees; the Company’s ability to
maintain the listing of its securities on the Nasdaq Capital
Market; the effect of the COVID-19 pandemic on the Company’s
business; the price of the Company’s securities may be volatile due
to a variety of factors, including changes in the competitive and
highly regulated industries in which the Company plans to operate,
variations in performance across competitors, changes in laws and
regulations affecting the Company’s business and changes in the
capital structure; the ability to implement business plans,
forecasts, and other expectations and identify and realize
additional opportunities; the risk of downturns and the possibility
of rapid change in the highly competitive industry in which the
Company operates; the risk that the Company and its current and
future collaborators are unable to successfully develop and
commercialize the Company’s products or services, or experience
significant delays in doing so; the risk that we will be unable to
continue to attract and retain third-party collaborators, including
collaboration partners and licensors; the risk that the Company may
never achieve or sustain profitability; the risk that the Company
will need to raise additional capital to execute its business plan,
which may not be available on acceptable terms or at all; the risk
that the Company experiences difficulties in managing its growth
and expanding operations; the risk that third-party suppliers and
manufacturers are not able to fully and timely meet their
obligations; the risk that the Company is unable to secure or
protect its intellectual property; the risk that the Company is
unable to secure regulatory approval for its product candidates;
general economic conditions; and other risks and uncertainties
indicated in the Current Report on Form 8-K filed with the SEC on
May 25, 2022 under “Risk Factors” and in other filings that have
been made or will be made with the SEC. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of Comera’s Current Report on Form
8-K filed with the SEC on May 25, 2022and other documents filed by
Comera from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Comera assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Comera can give no assurance that it
will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220615006162/en/
Comera Investor John Woolford ICR Westwicke
John.Woolford@westwicke.com
Comera Press Karen Chase ICR Westwicke
Karen.Chase@westwicke.com
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From Apr 2024 to May 2024
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From May 2023 to May 2024